biopharmaceuticals

Financial data/graphs
OrbiMed secures $1.86B for credit and royalty fund V
By Anthony Vecchione | 12:40 pm | August 06, 2025
The company intends to partner with healthcare, biopharmaceutical, medical device and diagnostic companies.